<DOC>
	<DOCNO>NCT03092128</DOCNO>
	<brief_summary>For patient GIST ( Gastrointestinal Stromal Tumor ) , Imatinib widely use GIST KIT PDGFRA sensitive mutation . From clinical point view , individual difference often occur different patient , lead diverse effect ADR drug effect . Meanwhile , drug effect adverse drug reaction significantly influence pharmacokinetic factor pharmacodynamic factor . In research , try establish sensitive method detect sensitive mutation plasma discover correlation somatic germline mutation , plasma trough concentration drug effect , association ADME-associated SNP , Target/Receptor/Pathway-associated SNP , trough concentration TKI adverse effect . Furthermore , vivo vitro research also crucial rational explanation clinical phenomenon .</brief_summary>
	<brief_title>A Retrospective Pharmacokinetics Pharmacogenomics Research Imatinib Gastrointestinal Stromal Tumor Treatment</brief_title>
	<detailed_description>The plasma concentration Imatinib establish . The ADME-associated SNPs include CYP3A4 , CYP3A4 , CYP1A1 , CYP2C9 , CYP2C19 , ABCB1 , ABCG2 , ABCC4 , SLC22A1 , SLCO1B3 . The Target/Receptor/Pathway-associated SNP include KIT , PDGFRA , PDGFRB , FLT1 , FLT3 , MAPK1 , SHC1 , CCL5 , CXCL14 . The somatic mutation include KIT , PDGFRA , BRAF .</detailed_description>
	<mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>The main patient entry criterion include : age≥ 18 year ; histologically cytologically proved GIST ; Eastern cooperative oncology group performance status ( ECOGPS ) ≤2 ; adequate hematological , renal , hepatic function . uncontrolled systemic disease , chemotherapy time inclusion . The protocol approve Ethical Committee Cancer Center Sun YatSen University ( CCSU ) , write informed consent obtain form patient .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Gastrointestinal stromal tumor ( GIST )</keyword>
	<keyword>Imatinib</keyword>
	<keyword>Pharmacogenetics</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Precision medicine</keyword>
	<keyword>Somatic germ-line mutation</keyword>
</DOC>